Altimmune, Inc. Total Revenue

• Altimmune, Inc. showed an increase of +105.0% in Total Revenue from 2024 to 2025.
• This data is from Altimmune, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
• XBRL data for this metric is available from 2010 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2017: $3.04 million | Q3 2017: $4.59 million | Q1 2018: $2.69 million | Q2 2018: $2.42 million | Q3 2018: $2.63 million | Q1 2019: $2.96 million | Q2 2019: $1.63 million | Q3 2019: $644.0 thousand | Q1 2020: $2.21 million | Q2 2020: $721.6 thousand | Q3 2020: $2.94 million | Q1 2021: $838.0 thousand | Q2 2021: $137.0 thousand | Q3 2021: $158.0 thousand | Q1 2022: $32.0 thousand | Q1 2022: $32.0 thousand | Q2 2022: $8.0 thousand | Q2 2022: $8.0 thousand | Q3 2022: $2.0 thousand | Q3 2022: $2.0 thousand | Q1 2023: $21.0 thousand | Q2 2023: $6.0 thousand | Q3 2023: $362.0 thousand | Q1 2024: $5.0 thousand | Q2 2024: $5.0 thousand | Q3 2024: $5.0 thousand | Q1 2025: $5.0 thousand | Q2 2025: $5.0 thousand | Q3 2025: $5.0 thousand.
• Over the full 12 years of available data (2010 to 2025), Altimmune, Inc.'s Total Revenue has declined by 99.8%.
• Historical annual values: Fiscal year 2025: $41.0 thousand | Fiscal year 2024: $20.0 thousand | Fiscal year 2023: $426.0 thousand | Fiscal year 2022: -$68.0 thousand | Fiscal year 2021: $4.41 million | Fiscal year 2021: $4.41 million | Fiscal year 2020: $8.19 million | Fiscal year 2019: $5.80 million | Fiscal year 2018: $10.33 million | Fiscal year 2017: $10.74 million | Fiscal year 2011: $24.27 million | Fiscal year 2010: $20.99 million.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026